海外の治験の状況【臨床研究情報ポータルサイト】

海外の治験の状況「1」での検索結果

絞り込み

199件の検索結果

Recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Crohn's Disease
American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
2017-04-04

Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
Crohn's Disease
American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
2017-04-04

Recruiting
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Crohn's Disease
American Samoa, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
2017-11-15

Recruiting
Phase III multicenter, double-blind, randomized, parallel-group study to evaluate safety and efficacy of Hercules plus Taxane HerceptinÂ® plus Taxane as First Line therapy in Her2-Positive Metastatic Breast cancer.
Drug will be tested in HER and MBC patients
Argentina, Austria, Brazil, Bulgaria, Canada, Chile, Czech Republic, Egypt, France, Georgia, Germany, Greece, Hungary, India, Latvia, Lebanon, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United States of America
2014-12-30

Recruiting
LYSO-PROVE - Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease
Lysosomal Storage Diseases;Gaucher Disease;Sphingolipidoses
Algeria, Egypt, Germany, Greece, India, Iran, Islamic Republic of, Israel, Mexico, Morocco, Russian Federation, Sweden, Tunisia, United States, Venezuela
2015-03-13

Recruiting
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
Severe Aplastic Anemia
Brazil, Hong Kong, Hungary, India, Italy, Korea, Republic of, Netherlands, Spain, Thailand, Turkey
2016-11-04

Recruiting
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GS 5745 COMBINED WITH MFOLFOX6 AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
-C168 Overlapping lesion of stomach Overlapping lesion of stomach;Overlapping lesion of stomach
Australia, Belgium, Colombia, Czech Republic, France, Germany, Hungary, Italy, Poland, Romania, Spain, Turkey, United Kindgdom, United States
2016-10-04

進捗状況

実施責任機関の所在地